Physician profile
Pranathi Koduru
NPI 1366721441
$464.83
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $116 · 2021: $11.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $174.07 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $129.75 | 2019-2020 | |
| Vifor Pharma, INC. | $48.23 | 2019 | |
| Exelixis INC. | $29.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.45 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.22 | 2019-2021 | |
| Janssen Biotech, INC. | $21.47 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranathi Koduru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.